Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab PK interaction with Paclitaxel in solid tumors
NCT01515306Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Primary completion
- Mar 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in solid tumor, sponsored by Eli Lilly and Company. Started Jul 2012; status: completed.
02
Drugs
ramucirumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01515306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515306.